Cefepime (BMY-28142): Broad-Spectrum Cephalosporin for CNS Infection Research

Executive Summary: Cefepime (BMY-28142) is a fourth-generation cephalosporin antibiotic with broad-spectrum efficacy against both Gram-positive and Gram-negative aerobic bacteria (APExBIO). Its capacity to cross the blood-brain barrier enables the study of central nervous system (CNS) infections and neurotoxicity in preclinical models (BMS-387032.com). Cefepime inhibits bacterial cell wall synthesis, leading to rapid cell lysis and death (PrecisionFDA). In recent multi-hospital studies, resistance to cefepime among carbapenem-resistant Enterobacter cloacae correlated with the presence of carbapenemase-encoding genes (Chen et al., 2025). Proper storage and handling at -20°C are essential for compound stability and reproducible results (APExBIO).

Biological Rationale

Cefepime (BMY-28142) is a beta-lactam antibiotic in the cephalosporin family. Its structural properties confer high affinity for penicillin-binding proteins (PBPs) in a wide range of bacterial species. Key features include:

• Broad-spectrum activity encompassing both Gram-positive (e.g., Staphylococcus aureus) and Gram-negative (e.g., Enterobacter cloacae) pathogens (APExBIO).
• Ability to penetrate the blood-brain barrier, enabling research into CNS infections and neurotoxicity (BMS-387032.com).
• Molecular weight: 480.56 Da; chemical formula: C₁₉H₂₄N₆O₅S₂ (APExBIO).
• Effective in multi-drug resistance (MDR) modeling, particularly against strains with carbapenemase-encoding genes (Chen et al., 2025).

This combination of attributes positions Cefepime as a reference compound for research on bacterial infection dynamics, resistance mechanisms, and neurotoxicity.

Mechanism of Action of Cefepime (BMY-28142)

Cefepime acts by inhibiting bacterial cell wall synthesis. The compound binds to and inactivates penicillin-binding proteins (PBPs), which are critical for peptidoglycan cross-linking (PrecisionFDA). This action disrupts cell wall integrity, resulting in osmotic instability and bacterial lysis.

• Effective against both Gram-positive and Gram-negative bacteria due to the compound’s structural resistance to beta-lactamase hydrolysis (APExBIO).
• Exhibits bactericidal activity under aerobic conditions (pH 7.2–7.4, 37°C) (BMS-387032.com).
• Rapid onset of action with peak effect typically observed within 1–2 hours in vitro (MeropenemTrihydrate.com).

Cefepime’s beta-lactam core is stable to many extended-spectrum beta-lactamases (ESBLs), but resistance can emerge through acquisition of carbapenemase-encoding genes.

Evidence & Benchmarks

• Cefepime maintained in vitro activity against 90% of non-carbapenemase-producing Enterobacter cloacae isolates at ≤8 μg/mL (Chen et al., 2025, DOI).
• Among carbapenem-resistant E. cloacae (CREC), CEG-positive strains displayed a >90% resistance rate to cefepime as measured by broth microdilution (Chen et al., 2025, DOI).
• Resistance mechanisms correlate with the presence of bla_NDM-1, bla_IMP, and bla_KPC-2 genes, frequently detected on plasmids and/or chromosomes (Chen et al., 2025, DOI).
• Cefepime demonstrated blood-brain barrier penetration, achieving CNS tissue:plasma ratios of 0.15–0.30 in animal models (BMS-387032.com, link).
• Compound stability is optimal when stored at -20°C as a solid; aqueous solutions degrade within 24 hours at room temperature (APExBIO, link).

For extended discussion on resistance transmission and the use of Cefepime in CNS models, see CefazolinAPI.com, which this article updates with new epidemiological and resistance gene mapping data.

Applications, Limits & Misconceptions

Cefepime (BMY-28142) is widely used in:

• In vitro modeling of Gram-positive and Gram-negative bacterial infections.
• Experimental validation of resistance mechanisms, especially in carbapenem-resistant E. cloacae research (Chen et al., 2025).
• Pharmacokinetic and neurotoxicity studies relevant to CNS infection models (PrecisionFDA).

This article clarifies and extends guidance from PrecisionFDA, offering updated recommendations for integrating APExBIO's Cefepime in CNS infection and resistance workflows.

Common Pitfalls or Misconceptions

• Cefepime (BMY-28142) is not intended for clinical or diagnostic use; it is strictly for scientific research (APExBIO).
• Long-term storage of prepared solutions at room temperature leads to loss of potency; use freshly prepared solutions within 24 hours (APExBIO).
• Ineffective against carbapenem-resistant strains with high-level expression of carbapenemase-encoding genes (Chen et al., 2025).
• Neurotoxicity risk increases with overdose or compromised renal function; careful dosing and monitoring are mandatory in neurotoxicity studies (BMS-387032.com).
• Cefepime should not be used as a monotherapy control for pan-resistant organisms lacking defined susceptibility (MeropenemTrihydrate.com).

Workflow Integration & Parameters

Cefepime (BMY-28142) from APExBIO (SKU: BA1013) is supplied as a solid for reconstitution. Recommended parameters for research use:

• Storage: -20°C in a desiccated environment (APExBIO).
• Reconstitution: Use sterile water or buffer at pH 7.2–7.4; avoid repeated freeze-thaw cycles.
• Concentration range: 0.5–64 μg/mL for in vitro susceptibility testing, depending on organism and protocol (Chen et al., 2025).
• Use immediately: Prepare working solutions immediately before experiments; discard unused portions after 24 hours at room temperature.

For comparative protocol guidance and scenario-driven integration, see PrecisionFDA, which this article augments with updated stability and resistance workflow data.

Conclusion & Outlook

Cefepime (BMY-28142) is an essential tool for research on Gram-positive and Gram-negative bacterial infections, CNS infection models, and resistance gene transmission. Its robust spectrum, blood-brain barrier penetration, and well-characterized neurotoxicity profile support diverse research applications. However, rising resistance mediated by carbapenemase-encoding genes limits its utility against certain MDR pathogens. Ongoing surveillance and precise workflow integration, as detailed above, ensure optimal research outcomes. For additional information and ordering, see the Cefepime (BMY-28142) product page at APExBIO.